World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
116
Citations
72345
World Ranking
4272
National Ranking
2335

Overview

Sundar Jagannath is affiliated with the Icahn School of Medicine at Mount Sinai in the United States. Their research spans fields such as Medicine and Biochemistry, Genetics and Molecular Biology, with a significant focus on subfields including Hematology, Oncology, Molecular Biology, Immunology, and Genetics.

The scientist's main topics of work include:

  • Multiple Myeloma Research and Treatments
  • CAR-T cell therapy research
  • Protein Degradation and Inhibitors
  • Biosimilars and Bioanalytical Methods
  • Peptidase Inhibition and Analysis
  • Monoclonal and Polyclonal Antibodies Research
  • Cancer Treatment and Pharmacology

They have contributed frequently to publication venues such as:

  • Clinical Lymphoma Myeloma & Leukemia (114 publications)
  • Blood (99 publications)
  • Journal of Clinical Oncology (34 publications)
  • Transplantation and Cellular Therapy (13 publications)
  • HemaSphere (11 publications)

Notable recent papers include:

  • "An inflammatory cytokine signature predicts COVID-19 severity and survival," 2020, Nature Medicine
  • "Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study," 2021, The Lancet
  • "Ciltacabtagene Autoleucel, an Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up," 2022, Journal of Clinical Oncology
  • "Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma," 2022, New England Journal of Medicine
  • "Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial," 2020, The Lancet

The scientist has collaborated extensively with colleagues including Samir Parekh, Joshua Richter, Deepu Madduri, Shambavi Richard, and Hearn Jay Cho. The number of collaborations with these co-authors ranges from 72 to 143 joint works.

Best Publications

  • International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma.

    S. Vincent Rajkumar;Meletios A. Dimopoulos;Antonio Palumbo;Joan Blade

  • A phase 2 study of bortezomib in relapsed, refractory myeloma.

    Paul G. Richardson;Bart Barlogie;James Berenson;Seema Singhal

  • An inflammatory cytokine signature predicts COVID-19 severity and survival.

    Diane Marie Del Valle;Seunghee Kim-Schulze;Hsin-Hui Huang;Noam D. Beckmann

  • International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma

    Shaji Kumar;Bruno Paiva;Kenneth C. Anderson;Brian Durie

  • Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant.

    Joan BladÉ;Diana Samson;Donna Reece;Jane Apperley

  • Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma

    Noopur Raje;Jesus Berdeja;Yi Lin;David Siegel

  • Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study

    Jesus G Berdeja;Deepu Madduri;Saad Z Usmani;Andrzej Jakubowiak

  • Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.

    Paul G. Richardson;Edie Weller;Sagar Lonial;Andrzej J. Jakubowiak

  • A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma

    S. Jagannath;B. Barlogie;J. Berenson;D. Siegel

  • Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study

    S. K. Kumar;J. H. Lee;J. J. Lahuerta;G. Morgan

  • A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma

    David S. Siegel;Thomas Martin;Michael Wang;Ravi Vij

  • Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma.

    Bart Barlogie;Sundar Jagannath;David H. Vesole;Sally Naucke

  • Graft-versus-myeloma effect: proof of principle

    Guido Tricot;David H. Vesole;Sundar Jagannath;Jennifer Hilton

  • Frequency, Characteristics, and Reversibility of Peripheral Neuropathy During Treatment of Advanced Multiple Myeloma With Bortezomib

    Paul G. Richardson;Hannah Briemberg;Sundar Jagannath;Patrick Y. Wen

  • Total Therapy With Tandem Transplants for Newly Diagnosed Multiple Myeloma

    B. Barlogie;S. Jagannath;K.R. Desikan;S. Mattox

  • Peripheral blood stem cell transplants for multiple myeloma: identification of favorable variables for rapid engraftment in 225 patients

    Guido Tricot;Sundar Jagannath;David Vesole;Jean Nelson

  • A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma

    Paul G. Richardson;Emily Blood;Constantine S. Mitsiades;Sundar Jagannath

  • Poor prognosis in multiple myeloma is associated only with partial or complete deletions of chromosome 13 or abnormalities involving 11q and not with other karyotype abnormalities

    Guido Tricot;Bart Barlogie;Sundar Jagannath;Dwayne Bracy

  • Oral selinexor-dexamethasone for triple-class refractory multiple myeloma

    Ajai Chari;Dan T Vogl;Maria Gavriatopoulou;Ajay K Nooka

  • International Myeloma Workshop Consensus Panel 1. Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1

    Sv Rajkumar;Jl Harousseau;B Durie;Kc Anderson

Frequent Co-Authors

David H. Vesole
David H. Vesole Rutgers, The State University of New Jersey
Bart Barlogie
Bart Barlogie Mount Sinai Hospital
Guido Tricot
Guido Tricot University of Iowa
Nikhil C. Munshi
Nikhil C. Munshi Harvard University
Paul G. Richardson
Paul G. Richardson Harvard University
David S. Siegel
David S. Siegel Hackensack University Medical Center
Ravi Vij
Ravi Vij Washington University in St. Louis
Sagar Lonial
Sagar Lonial Emory University
Robert Z. Orlowski
Robert Z. Orlowski The University of Texas MD Anderson Cancer Center
Kenneth C. Anderson
Kenneth C. Anderson Harvard University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring related online degrees opens up a variety of career opportunities in healthcare beyond traditional medical school. Many students are now considering online pharmacist programs as a flexible option to pursue a pharmacy career while balancing other commitments.

If you are interested in health data and technology, an him degree online can prepare you for roles in health information management—an essential field for modern healthcare operations.

For those seeking quick entry points into healthcare with specialized skills, medical billing and coding online courses offer targeted training for in-demand jobs managing patient records and supporting the medical billing cycle.

Nursing remains a strong and versatile career path. Among the most cost-effective routes are cheapest online acute care nurse practitioner programs, which prepare students for advanced clinical roles in acute care environments.

By exploring these online degree pathways, you can find flexible and affordable options to start or advance your healthcare career.

Best Scientists Citing Sundar Jagannath

Trending Scientists